Introducing NovaSeq This is the second part of my “everything you wanted to know about NovaSeq blog and in it I’ll finish up by discussing some of the challenges the instrument presents for Core Labs and their users, and the costs of running NovaSeq compared to […]
Introducing NovaSeq This is the first part of a 2 part blog. Part 1 “everything you wanted to know about NovaSeq” covers the technical aspects of NovaSeq, Illumina’s latest sequencer launched on Jan 9th 2017. The instrument is very clearly the next proper step in Illumina technology, which […]
I thought I’d follow Keith’s lead and make my own suggestions for what might be revealed during Illumina’s presentation at this years JPMorgan event. All the great announcements, by Illumina and everyone else, used to be made at the AGBT meeting in February and that gave […]
Illumina’s patterned flowcells were a major change to their core technology. It was a change that was a long time coming, with patterned flowcells being discussed many years ago at AGBT. Any major change can throw up nasty surprises, and unfortunately the new ExAmp clustering […]
Single-cell sequencing is making waves with many exciting developments over the last couple of years. Hardware is available from the companies like 10X Genomics, Fluidigm, Wafergen, BioRad (see GenomeWeb), RainDance (see GenomeWeb), Dolomite Bio. Chemistry for RNA and Genome sequencing such as SMART-Seq V4 and TruPrime, opens up all sorts […]
The latest round of fundraising by ONT brought in over $100 million, that makes a total of around $X million invested over the last X years. This round of funding was led by GT Healthcare, a Hong Kong based investment group. According to the Financial Times […]
Qiagen are now finally selling the GeneReader after a hiatus of several years. This was caused by issues getting a working instrument out of the original IBS technology, and also held, temporarily, up by recent Illumina litigation. GenomeWeb covered the relaunch back in November. Qiagens updated […]
Illumina stock dropped 25% after a hammering by the stock market with their recent announcements that Q3 revenues would be 3.4% lower than expected at just $607 million. This makes Illumina a much more attractive acquisition (although I doubt this summers rumours of a Thermo […]
This article was commissioned by Lexogen GmbH. My lab has been performing RNA-seq for many years, and is currently building new services around single-cell RNA-seq. Fluidigm’s C1, academic efforts such as Drop-seq and inDrop, and commercial platforms from 10X Genomics, Dolomite Bio, Wafergen, Illumina/BioRad, RainDance and others makes establishing […]
Multiplexing is the default option for most of the work being carried out in my lab, and it is one of the reasons Illumina has been so successful. Rather than the one-sample-per-lane we used to run when a GA1 generated only a few million reads […]
